TITLE

FDA advisers uneasy about long-term bisphosphonate use

AUTHOR(S)
Traynor, Kate
PUB. DATE
November 2011
SOURCE
American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2006
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that FDA's panel of experts advised against the long-term use of bisphosphonates for osteoporosis, and suggested that biophosphonate therapy be reevaluated on a periodic basis. It mentions the National Osteoporosis Foundation recommendation on biophosphonate use, and includes comments from FDA Clinical Team Leader Theresa Kehoe, who stated that bisphosphonates are effective in fracture-prevention when used for five years, but show no benefits beyond that duration.
ACCESSION #
66903638

 

Related Articles

  • DMPA: Time to repeal black box warning?  // Contraceptive Technology Update;Oct2011, Vol. 32 Issue 10, p112 

    A recently published editorial is calling for the repeal of the black box warning to the labeling for the contraceptive injection, depot medroxyprogesterone acetate (DMPA). The Food and Drug Administration added the warning in 2004 advising that prolonged use might result in bone mineral density...

  • FDA: Possible increased risk of thigh bone fracture with bisphosphonates Labeling change adds warning about possible risks of long-term use of osteoporosis drugs.  // Biomedical Market Newsletter;12/20/2010, p52 

    The article reports that the U.S. Food & Drug Administration (FDA) has warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates. It is a class of drugs which is used to prevent and treat osteoporosis....

  • Possible Fracture Risk With Osteoporosis Drugs.  // Biomedical Market Newsletter;12/20/2010, p56 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take drugs known as bisphosphonates to treat osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these prescription...

  • FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures.  // Biomedical Market Newsletter;12/20/2010, p57 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take bisphosphonates, a kind of drugs used for treating osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these...

  • Osteoporosis in men: who should we treat? Compston, Juliet // BMJ: British Medical Journal;7/12/2014, Vol. 349 Issue 7966, pg4229 

    The author discusses research which investigated diagnosis and treatment of osteoporosis in men, conducted by Ensrud and colleagues, published within the issue. Topics addressed include the use of bone mineral density (BMD) measurements as possible diagnostic criteria, the analysis of...

  • Bisphosphonate therapy: how long is long enough? McClung, M. // Osteoporosis International;May2015, Vol. 26 Issue 5, p1455 

    The author discusses the role of bisphosphonates in bone remodeling for the treatment of osteoporosis. According to the author, clinical trial data have shown that taking an oral bisphosphonate for less than six months has little effect on fracture risk, and a reduction in vertebral fracture...

  • Recent advances in the pathogenesis and treatment of osteoporosis. Curtis, Elizabeth M.; Moon, Rebecca J.; Dennison, Elaine M.; Harvey, Nicholas C.; Cooper, Cyrus // Clinical Medicine;2015 Supplement, Vol. 15, ps92 

    Over recent decades, the perception of osteoporosis has changed from that of an inevitable consequence of ageing, to that of a well characterised and treatable chronic non-communicable disease, with major impacts on individuals, healthcare systems and societies. Characterisation of its...

  • New contraindication added to Reclast drug label.  // Reactions Weekly;9/10/2011, Issue 1368, p3 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on August 30, 2011 to the drug label for Reclast (zoledronic acid), which caution its association with risks of renal failure in patients with a history of, or risk factors for, renal impairment.

  • FDA advisory panels call for clarification on duration of bisphosphonate use. Foster, Melissa // Endocrine Today;Oct2011, Vol. 9 Issue 10, p1 

    The article reports that the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has called for clarifications to the duration of use in bisphosphonate drug labeling.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics